Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study
Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at...
obinutuzumab
Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022
The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive...
Promising New Lupus Treatments Highlighted ACR Annual Meeting
Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR...
LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020
30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways
Results from...
Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments
November 14, 2019
The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly...
Lupus Research Alliance Response to Positive Trial Testing Obinutuzumab (Gazyva®) for Lupus Nephritis
NEW YORK, Nov. 10, 2019 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by...
LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting
Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways
Results...
FDA Expedites Existing Drug Gazyva for Lupus Nephritis
September 18, 2019
The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy...
Lupus Research Alliance Pleased to Share Positive News about Potential Drug for Lupus Nephritis
NEW YORK, NY. June 11, 2019. The Lupus Research Alliance is pleased to share positive topline results from a...